

Financial Tear Sheet

Corporate Profile

Investors

BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. Its lead asset, immuno-oncology agent Plinabulin, is currently in multiple global registration studies, for the prevention of chemotherapy-induced neutropenia and as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Company also has a robust internal early-stage pipeline, and a research collaboration with Fred Hutchinson Cancer Research Center and University of Washington exploring the ubiquitin ligase protein to target and promote the destruction of disease causing proteins, such as oncogenes.

Led by a highly qualified management team with proven pharmaceutical experience and a combined 30+ drugs brought to market, and a unique, highly scalable business model that integrates clinical resources in the U.S. and China, BeyondSpring believes that it is well positioned for expeditious progress towards regulatory approvals and commercialization in a cost-efficient manner.

Primary IR Contact

Laura Perry / Joe Rayne

Argot Partners

Phone: 212.600.1902

E-mail:

BeyondSpring@argotpartners.com

Stock Information

BYSI (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$30.00
Change (%)	▼ 1.1 (3.54%)
Volume	60,363
52 Week Low	\$19.55
Market Cap	\$698,372,332
Rolling EPS	-4.94
PE Ratio	0
Shares Outstanding	22,455,702



Recent Press Releases & Upcoming Events

April 17, 2018

[BeyondSpring Presents Lead Asset's Mechanism Data for Prevention of Chemotherapy-Induced Neutropenia](#)

April 3, 2018

[BeyondSpring Files Its 2017 Annual Report on Form 20-F](#)

April 3, 2018

[BeyondSpring Provides Operational Update and Fourth-Quarter and Full-Year 2017 Financial Results](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
April 3, 2018	20-F
March 27, 2018	6-K
February 21, 2018	6-K
February 14, 2018	SC 13G

Corporate Governance

Lan Huang, Ph.D.	Co-founder, Chairman & CEO
Ramon Mohanlal, M.D., Ph.D.	Chief Medical Officer
Edward Dongheng Liu	Chief Financial Officer
G. Kenneth Lloyd, Ph.D.	Chief Scientific Officer
Gordon L. Schooley, Ph.D.	Chief Regulatory Officer